Integrated Diagnostics Holdings annual cash and equivalents
2021
2022
2023
2024
2025
Integrated Diagnostics Holdings Cash & Equivalents Growth & History (IDHC)
Integrated Diagnostics Holdings's cash and equivalents was E£1.67B for fiscal 2025.
View full Integrated Diagnostics Holdings company overviewIntegrated Diagnostics Holdings annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | E£1.67B | E£482.7M | +40.63% |
| 2024 | 2024-12-31 | E£1.19B | E£513.8M | +76.21% |
| 2023 | 2023-12-31 | E£674.3M | E£25.7M | +3.97% |
| 2022 | 2022-12-31 | E£648.5M | −E£242.9M | −27.25% |
| 2021 | 2021-12-31 | E£891.5M | — | — |
Integrated Diagnostics Holdings cash and equivalents trends
Between the periods ended 2021-12-31 and 2025-12-31, Integrated Diagnostics Holdings's cash and equivalents increased from E£891.5M to E£1.67B, a change of E£779.3M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Integrated Diagnostics Holdings source filings ↗